Epizyme Reports Third Quarter 2017 Operating Results and Company Updates Nov 1, 2017 04:02PM
Epizyme Announces Date of Third Quarter 2017 Financial Results Oct 25, 2017 06:30AM
Epizyme to Participate in Upcoming Investor Conferences Aug 30, 2017 06:30AM
Epizyme Announces Leadership Transition for Finance Organization Aug 15, 2017 06:30AM
Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress Aug 4, 2017 06:30AM
View Older Stories

Aug 1, 2017 06:30AM US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations
Jul 31, 2017 06:30AM Epizyme Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
Jul 24, 2017 04:11PM Epizyme (EPZM) Reports Tazemetostat to be Evaluated in NCI’s Recently Initiated NCI-COG Pediatric MATCH Trial
Jul 24, 2017 04:05PM Epizyme Announces Tazemetostat to be Evaluated in NCI’s Recently Initiated NCI-COG Pediatric MATCH Trial
Jun 26, 2017 06:31AM Epizyme (EPZM) Expands Collaboration to Study Tazemetostat and TECENTRIQ Combination in NSCLC with Genentech
Jun 26, 2017 06:30AM Epizyme Expands Clinical Collaboration to Study Tazemetostat and TECENTRIQ® Combination in NSCLC
Jun 21, 2017 06:33AM Epizyme (EPZM) Says Tazemetostat Granted Orphan Drug Designation for Treatment of Soft Tissue Sarcoma
Jun 21, 2017 06:30AM Epizyme Announces Tazemetostat Granted Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma
Jun 14, 2017 08:36AM Epizyme (EPZM) Announces Positive Interim Data from Phase 2 Trial for Tazemetostat in R/R Follicular Lymphoma and DLBCL Patients
Jun 14, 2017 08:30AM Epizyme Reports Positive Interim Data from Phase 2 Trial for Tazemetostat in Relapsed or Refractory Follicular Lymphoma and DLBCL Patients
May 18, 2017 06:51AM Epizyme (EPZM) Identifies Path Toward Submission for Accelerated Approval of Tazemetostat to Treat Epithelioid Sarcoma; Says New Clinical Data to be Presented at ASCO
May 18, 2017 06:00AM Epizyme Announces Path Toward Tazemetostat Registration in Epithelioid Sarcoma and Reports New Clinical Data to be Presented at ASCO
May 8, 2017 07:00AM Epizyme Reports First Quarter 2017 Results and Provides Corporate Update
May 4, 2017 06:30AM Epizyme Earns $10 Million Milestone Payment from GlaxoSmithKline for Initiation of GLP Toxicology Studies with Novel Methyltransferase Inhibitor
Apr 25, 2017 06:32AM Epizyme (EPZM) Receives Tazemetostat Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML
Apr 25, 2017 06:30AM Epizyme Announces Tazemetostat Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML
Apr 20, 2017 10:05AM Epizyme Announces Date of First Quarter 2017 Financial Results and Tazemetostat Data Presentations at ASCO
Mar 29, 2017 06:32AM Epizyme (EPZM) to Offer New Pre-Clinical Data on Tazemetostat/Epigenetic Target Identification Efforts at AACR Annual Meeting
Mar 29, 2017 06:30AM Epizyme to Present New Preclinical Data on Tazemetostat and Epigenetic Target Identification Efforts at AACR Annual Meeting
Mar 9, 2017 06:32AM Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals
Mar 9, 2017 06:30AM Epizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company
Feb 27, 2017 09:06AM Epizyme Announces 2016 Fourth Quarter and Full-Year Results Conference Call Date and March Investor Conferences
Nov 3, 2016 06:30AM Epizyme Provides Update on Execution of Clinical Program and Reports Third Quarter 2016 Financial Results
Sep 29, 2016 06:30AM Epizyme Appoints Pamela Strode as Vice President, Regulatory Affairs and Quality Assurance
May 12, 2016 08:00AM Epizyme to Present Data From the Tazemetostat Non-Hodgkin Lymphoma Program at American Society for Hematology Meeting on Lymphoma Biology
May 9, 2016 06:40AM Epizyme Announces First Quarter 2016 Financial Results and Provides Update on Execution Against Multi-Year Company Vision
May 9, 2016 06:35AM Epizyme Announces Collaboration with Lymphoma Study Association to Evaluate Combination of Tazemetostat with R-CHOP in Front-line Non-Hodgkin Lymphoma
May 6, 2016 08:00AM Epizyme Continues to Build Senior Leadership Team with Appointment of Matthew Ros as Chief Operating Officer
May 4, 2016 06:36AM Epizyme's (EPZM) Tazemetostat IND Submission Accepted by U.S. FDA
May 4, 2016 06:35AM Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Mesothelioma
May 2, 2016 08:00AM Epizyme to Report First Quarter 2016 Financial Results and Provide Corporate Update on May 9, 2016 and to Participate in Upcoming May Conferences
Apr 25, 2016 08:04AM Epizyme (EPZM) Appoints New Chief Business Officer
Apr 25, 2016 08:00AM Epizyme Broadens Executive Leadership Team with Experienced New Officer and Senior Management
Apr 18, 2016 09:06AM Epizyme (EPZM) Announcess Presentation of Data from Studies of Food Intake on Tazemetostat
Apr 18, 2016 09:01AM Epizyme Presents Data from Tazemetostat Clinical Pharmacology Studies at American Association for Cancer Research Annual Meeting 2016
Mar 17, 2016 08:04AM Epizyme (EPZM) Will Present New Data for EPZ-6438 at AACR 2016
Mar 17, 2016 08:00AM Epizyme to Present New Data in Support of Tazemetostat Clinical Development Program
Mar 9, 2016 06:31AM Epizyme Announces 2015 Financial Results and Financial Guidance
Mar 9, 2016 06:30AM Epizyme Unveils Corporate Strategy to Guide Efforts over Next Five Years
Mar 2, 2016 06:30AM Epizyme to Report 2015 Financial Results and Provide Business Updates on March 9, 2016
Feb 8, 2016 08:01AM Epizyme's (EPZM) Tazemetostat Granted FDA Orphan Drug Designation
Feb 8, 2016 08:00AM Epizyme Announces Tazemetostat Granted Orphan Drug Designation for Malignant Rhabdoid Tumors by U.S. FDA
Feb 1, 2016 08:00AM Epizyme to Present at Upcoming Investor Conferences
Dec 30, 2015 08:00AM Epizyme (EPZM) Commences Dosing in Tazemetostat Phase 2 for Genetically Defined Tumors
Dec 30, 2015 08:00AM Epizyme Announces First Patient Dosed in Global Clinical Program Evaluating Tazemetostat in Genetically Defined Solid Tumors
Dec 28, 2015 08:03AM Epizyme's (EPZM) IND for Tazemetostat as DLBCL Treatment Accepted by FDA
Dec 28, 2015 08:00AM Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Diffuse Large B-cell Lymphoma
Dec 7, 2015 08:00AM Epizyme Presents Updated Data from Ongoing Phase 1 Study of Tazemetostat Showing Objective, Durable Responses in Relapsed or Refractory Non-Hodgkin Lymphoma
Nov 24, 2015 08:00AM Epizyme, Inc. to Present at Piper Jaffray Conference on December 1, 2015
Nov 9, 2015 06:30AM Epizyme Announces Third Quarter 2015 Financial Results and Provides Corporate Update
View Older Stories